Use of proinsulin for immune system modulation
US9669073B2 · kind B2 · utility
6Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2015 |
| Grant date | Jun 6, 2017 |
| Priority date | — |
| Expiry date | Mar 31, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a composition for promoting immune activity including a protein selected from the group consisting of dimeric proinsulin, C-peptide partially deleted mutant of dimeric proinsulin, and C-peptide partially deleted mutant of monomeric proinsulin as an effective component and a composition for immunosuppression including C-peptide site of proinsulin as an effective component, and the dimeric proinsulin, the C-peptide partially deleted mutant of dimeric proinsulin, and the C-peptide partially deleted mutant of monomeric proinsulin can be applied as immune enhancers to diabetic patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.